Our Team

A diverse and interconnected team

Arch Biopartners Scientists and Management teams

The company is led by experienced groups of scientists with an executive, board and advisors with scientific, pharmaceutical, biotechnology and corporate financial experience.
  • LSALT Peptide (Metablok) and MetaMX are led by Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn Ph. D. at the University of Calgary
  • AB569 and Respiratory Pseudomonas is led by Dr. Daniel J. Hassett Ph. D. at the University of Cincinnati, College of Medicine
  • BORG Peptide is led by Dr. Randall Irvin Ph. D., Dr. Dongyang Li Ph. D. and Dr. Elisabeth Davis Ph. D. at the University of Alberta
  • The Treatments for Inflammation Team is led by Dr. Daniel Muruve Ph. D., Dr. Justin Macdonald Ph. D. and Dr. Paul Beck at the University of Calgary
  • Executives and Founders, CEO Richard Muruve, CSO Dr. Daniel Muruve Ph. D. and CFO (acting) Andrew Bishop form the management team
  • Board of Directors, includes a group of key directors and strategic advisors
Contact Arch Biopartners
Stay connected!

Recent Press Releases